EUVIMEDEUVIMED entdecken
Open Access

Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome

Roxane Labrosse iD, Julia I Chu, Myriam A Armant, John K Everett, Danilo Pellin iD, Niharika Kareddy, Andrew L Frelinger, Lauren A Henderson, Amy E O'Connell, Amlan Biswas, Jet Coenen-van der Spek iD, Alexandra Miggelbrink und 33 weitere

Blood · 2023

DOI: 10.1182/blood.2022019117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Roxane Labrosse und 44 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Wiskott-Aldrich Syndrome, Hematopoietic Stem Cell Transplantation, Eczema. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder characterized by combined immunodeficiency, eczema, microthrombocytopenia, autoimmunity, and lymphoid malignancies. Gene therapy (GT) to modify autologous CD34+ cells is an emerging alternative treatment with advantages over standard allogeneic hematopoietic stem cell transplantation for patients who lack well-matched donors, avoiding graft-versus-host-disease. We report the outcomes of a phase 1/2 clinical trial in which 5 patients with severe WAS underwent GT using a self-inactivating lentiviral vector expressing the human WAS complementary DNA under the control of a 1.6-kB fragment of the autologous promoter after busulfan and fludarabine conditioning. All patients were alive and well with sustained multilineage vector gene marking (median follow-up: 7.6 years). Clinical improvement of eczema, infections, and bleeding diathesis was universal. Immune function was consistently improved despite subphysiologic levels of transgenic WAS protein expression. Improvements in platelet count and cytoskeletal function in myeloid cells were most prominent in patients with high vector copy number in the transduced product. Two patients with a history of autoimmunity had flares of autoimmunity after GT, despite similar percentages of WAS protein–expressing cells and gene marking to those without autoimmunity. Patients with flares of autoimmunity demonstrated poor numerical recovery of T cells and regulatory T cells (Tregs), interleukin-10–producing regulatory B cells (Bregs), and transitional B cells. Thus, recovery of the Breg compartment, along with Tregs appears to be protective against development of autoimmunity after GT. These results indicate that clinical and laboratory manifestations of WAS are improved with GT with an acceptable safety profile. This trial is registered at clinicaltrials.gov as #NCT01410825.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wiskott-Aldrich SyndromeHematopoietic Stem Cell TransplantationEczemaHumansWiskott-Aldrich Syndrome ProteinHematopoietic Stem CellsGenetic Therapy

Substanzen

Wiskott-Aldrich Syndrome Protein

Autor:innen und Institutionen

  • Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Immune Deficiency-Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Division of Allergy and Immunology, Department of Pediatrics, CHU Sainte-Justine, University of Montreal, Montreal, QC, Canada.
  • Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA.
  • Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Gene Therapy Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA.

ORCID-Profile: Roxane Labrosse, Danilo Pellin, Jet Coenen-van der Spek, Claudia Fiorini, Vito Adrian Cantu, Jason Jaroslavsky, Quan-Zhen Li, Jennifer S Whangbo, Safa Baris, Lisa R Forbes Satter, Akihiko Saitoh, Yuta Aizawa, Mai Anh Thi Nguyen, Anne Galy, Luigi D Notarangelo, David A Williams, Sung-Yun Pai

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS

Zitieren

APA

Labrosse, R., Chu, J. I., Armant, M. A., Everett, J. K., Pellin, D., Kareddy, N., Frelinger, A. L., Henderson, L. A., O'Connell, A. E., Biswas, A., Coenen-van der Spek, J., Miggelbrink, A., Fiorini, C., Adhikari, H., Berry, C. C., Cantu, V. A., Fong, J., Jaroslavsky, J., Karadeniz, D. F., …, & Pai, S. Y. (2023). Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood. https://doi.org/10.1182/blood.2022019117

Vancouver

Labrosse R, Chu JI, Armant MA, Everett JK, Pellin D, Kareddy N, et al. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood. 2023. doi:10.1182/blood.2022019117

BibTeX
@article{Labrosse2023,
  author = {Labrosse, Roxane and Chu, Julia I and Armant, Myriam A and Everett, John K and Pellin, Danilo and Kareddy, Niharika and Frelinger, Andrew L and Henderson, Lauren A and O'Connell, Amy E and Biswas, Amlan and Coenen-van der Spek, Jet and Miggelbrink, Alexandra and Fiorini, Claudia and Adhikari, Hriju and Berry, Charles C and Cantu, Vito Adrian and Fong, Johnson and Jaroslavsky, Jason and Karadeniz, Derin F and Li, Quan-Zhen and Reddy, Shantan and Roche, Aoife M and Zhu, Chengsong and Whangbo, Jennifer S and Dansereau, Colleen and Mackinnon, Brenda and Morris, Emily and Koo, Stephanie M and London, Wendy B and Baris, Safa and Ozen, Ahmet and Karakoc-Aydiner, Elif and Despotovic, Jenny M and Forbes Satter, Lisa R and Saitoh, Akihiko and Aizawa, Yuta and King, Alejandra and Nguyen, Mai Anh Thi and Vu, Vy Do Uyen and Snapper, Scott B and Galy, Anne and Notarangelo, Luigi D and Bushman, Frederic D and Williams, David A and Pai, Sung-Yun},
  title = {Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022019117}
}
Kostenlos starten →